The Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) treatment is expected to reach USD 2,249,032.64 thousand by 2030, from USD 966,456.13 thousand in 2022, growing at the CAGR of 11.6% in the forecast period of 2023 to 2030. Market Segmentation Asia-Pacific Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific Industry Trends and Forecast to 2030 Overview of Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics Driver • Increasing prevalence and incidence of acute lung injury in the market Restraint • High cost of device and treatment Opportunity • Strategic initiatives joined with new product launches by market players Market Players Some of the major market players operating in the Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge AB. • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • Drägerwerk AG & Co. KGaA • NIPRO • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • WEINMANN Emergency Medical Technology GmbH + Co. KG • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd. • Besmed Health Business Corp.

1 INTRODUCTION 22 1.1 OBJECTIVES OF THE STUDY 22 1.2 MARKET DEFINITION 22 1.3 OVERVIEW OF ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22 1.4 LIMITATIONS 24 1.5 MARKETS COVERED 24 2 MARKET SEGMENTATION 26 2.1 MARKETS COVERED 26 2.2 GEOGRAPHICAL SCOPE 27 2.3 YEARS CONSIDERED FOR THE STUDY 28 2.4 CURRENCY AND PRICING 28 2.5 DBMR TRIPOD DATA VALIDATION MODEL 29 2.6 MULTIVARIATE MODELLING 32 2.7 TYPE LIFELINE CURVE 32 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33 2.9 DBMR MARKET POSITION GRID 34 2.10 MARKET END USER COVERAGE GRID 35 2.11 VENDOR SHARE ANALYSIS 36 2.12 SECONDARY SOURCES 37 2.13 ASSUMPTIONS 37 3 EXECUTIVE SUMMARY 38 4 PREMIUM INSIGHTS 41 4.1 PESTEL ANALYSIS 42 4.2 PORTER’S FIVE FORCES 43 4.3 INSURANCE REIMBURSEMENT 44 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44 4.3.3 ABBOTT CODING GUIDE FOR ECMO 45 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45 4.3.5 CERN HEALTH INSURANCE SCHEME 46 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46 4.3.7 AMERICAN HOSPITAL ASSOCIATION 47 4.4 PIPELINE ANALYSIS 48 4.5 PRICING ANALYSIS 50 5 MARKET OVERVIEW 51 5.1 DRIVERS 53 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54 5.2 RESTRAINTS 55 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55 5.2.2 HIGH COST OF DEVICES AND TREATMENT 55 5.3 OPPORTUNITIES 56 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57 5.4 CHALLENGES 58 5.4.1 STRINGENT RULES & REGULATIONS 58 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59 6 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60 6.1 OVERVIEW 61 6.2 MECHANICAL VENTILATION 64 6.2.1 HIGH-FLOW NASAL O2 65 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65 6.2.4 PRONE POSITION VENTILATION 65 6.2.5 OTHERS 66 6.3 CORTICOSTEROIDS 66 6.3.1 METHYLPREDNISOLONE 67 6.3.2 DEXAMETHASONE 67 6.3.3 OTHERS 67 6.4 ANTIVIRAL MEDICATION 68 6.4.1 RIBAVIRIN 69 6.4.2 OSELTAMIVIR 69 6.4.3 OTHERS 69 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69 6.6 TOCILIZUMAB 70 6.7 OTHERS 70 7 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71 7.1 OVERVIEW 72 7.2 SEPSIS 75 7.3 INHALATION OF HARMFUL SUBSTANCES 75 7.4 SEVERE PNEUMONIA 76 7.5 OTHERS 76 8 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77 8.1 OVERVIEW 78 8.2 PARENTERAL 81 8.2.1 INTRAVENOUS 81 8.2.2 INTRAMUSCULAR 81 8.3 ORAL 82 8.4 OTHERS 82 9 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83 9.1 OVERVIEW 84 9.2 HOSPITALS 87 9.3 SPECIALTY CLINICS 87 9.4 HOME HEALTHCARE 88 9.5 OTHERS 88 10 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89 10.1 OVERVIEW 90 10.2 DIRECT TENDER 93 10.3 HOSPITAL PHARMACY 93 10.4 RETAIL PHARMACY 94 10.5 ONLINE PHARMACY 94 11 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95 11.1 ASIA-PACIFIC 97 11.1.1 JAPAN 103 11.1.2 CHINA 108 11.1.3 INDIA 113 11.1.4 SOUTH KOREA 118 11.1.5 AUSTRALIA 123 11.1.6 SINGAPORE 128 11.1.7 THAILAND 133 11.1.8 MALAYSIA 138 11.1.9 INDONESIA 143 11.1.10 PHILIPPINES 148 11.1.11 REST OF ASIA-PACIFIC 153 12 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 154 12.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 154 13 SWOT ANALYSIS 155 14 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 156 14.1 GILEAD SCIENCES INC 156 14.1.1 COMPANY SNAPSHOT 156 14.1.2 REVENUE ANALYSIS 157 14.1.3 COMPANY SHARE ANALYSIS 157 14.1.4 PRODUCT PORTFOLIO 158 14.1.5 RECENT DEVELOPMENT 158 14.2 TERUMO CORPORATION 159 14.2.1 COMPANY SNAPSHOT 159 14.2.2 REVENUE ANALYSIS 159 14.2.3 COMPANY SHARE ANALYSIS 160 14.2.4 PRODUCT PORTFOLIO 160 14.2.5 RECENT DEVELOPMENT 160 14.3 GETINGE 161 14.3.1 COMPANY SNAPSHOT 161 14.3.2 REVENUE ANALYSIS 161 14.3.3 COMPANY SHARE ANALYSIS 162 14.3.4 PRODUCT PORTFOLIO 162 14.3.5 RECENT DEVELOPMENT 162 14.4 LIVANOVA PLC 163 14.4.1 COMPANY SNAPSHOT 163 14.4.2 REVENUE ANALYSIS 163 14.4.3 COMPANY SHARE ANALYSIS 164 14.4.4 PRODUCT PORTFOLIO 164 14.4.5 RECENT DEVELOPMENTS 164 14.5 MEDTRONIC 165 14.5.1 COMPANY SNAPSHOT 165 14.5.2 REVENUE ANALYSIS 165 14.5.3 COMPANY SHARE ANALYSIS 166 14.5.4 PRODUCT PORTFOLIO 166 14.5.5 RECENT DEVELOPMENTS 166 14.6 ARMSTRONG MEDICAL 167 14.6.1 COMPANY SNAPSHOT 167 14.6.2 PRODUCT PORTFOLIO 167 14.6.3 RECENT DEVELOPMENT 167 14.7 BESMED HEALTH BUSINESS CORP 168 14.7.1 COMPANY SNAPSHOT 168 14.7.2 PRODUCT PORTFOLIO 168 14.7.3 RECENT DEVELOPMENTS 169 14.8 DRÄGERWERK AG & CO. KGAA 170 14.8.1 COMPANY SNAPSHOT 170 14.8.2 REVENUE ANALYSIS 170 14.8.3 PRODUCT PORTFOLIO 171 14.8.4 RECENT DEVELOPMENTS 171 14.9 EUROSETS 172 14.9.1 COMPANY SNAPSHOT 172 14.9.2 PRODUCT PORTFOLIO 172 14.9.3 RECENT DEVELOPMENT 172 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 173 14.10.1 COMPANY SNAPSHOT 173 14.10.2 REVENUE ANALYSIS 173 14.10.3 PRODUCT PORTFOLIO 174 14.10.4 RECENT DEVELOPMENTS 174 14.11 FRESENIUS SE & CO. KGAA 175 14.11.1 COMPANY SNAPSHOT 175 14.11.2 REVENUE ANALYSIS 175 14.11.3 PRODUCT PORTFOLIO 176 14.11.4 RECENT DEVELOPMENT 176 14.12 HAMILTON MEDICAL 177 14.12.1 COMPANY SNAPSHOT 177 14.12.2 PRODUCT PORTFOLIO 177 14.12.3 RECENT DEVELOPMENT 177 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 178 14.13.1 COMPANY SNAPSHOT 178 14.13.2 PRODUCT PORTFOLIO 178 14.13.3 RECENT DEVELOPMENT 178 14.14 NIPRO 179 14.14.1 COMPANY SNAPSHOT 179 14.14.2 REVENUE ANALYSIS 179 14.14.3 PRODUCT PORTFOLIO 180 14.14.4 RECENT DEVELOPMENT 180 14.15 PFIZER INC 181 14.15.1 COMPANY SNAPSHOT 181 14.15.2 REVENUE ANALYSIS 181 14.15.3 PRODUCT PORTFOLIO 182 14.15.4 RECENT DEVELOPMENT 182 14.16 RESMED 183 14.16.1 COMPANY SNAPSHOT 183 14.16.2 REVENUE ANALYSIS 183 14.16.3 PRODUCT PORTFOLIO 184 14.16.4 RECENT DEVELOPMENT 184 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 185 14.17.1 COMPANY SNAPSHOT 185 14.17.2 PRODUCT PORTFOLIO 185 14.17.3 RECENT DEVELOPMENT 185 15 QUESTIONNAIRE 186 16 RELATED REPORTS 189